First filing for Takeda's once-weekly DPP-4 inhibitor but prospects limited?
This article was originally published in Scrip
Takeda has made the first approval filing for its once-weekly DPP-4 inhibitor trelagliptin (SYR-472), in Japan for the treatment of type 2 diabetes, although some analysts are cautious over its sales prospects despite the apparent convenience benefits.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
Tislelizumab meets overall survival endpoint in later-line NSCLC at planned interim analysis, but faces exploding competition in the Chinese immuno-oncology sector.